BR112022019387A2 - Derivados de aminopirimidina e seu uso como moduladores de receptores de aril hidrocarbonetos - Google Patents

Derivados de aminopirimidina e seu uso como moduladores de receptores de aril hidrocarbonetos

Info

Publication number
BR112022019387A2
BR112022019387A2 BR112022019387A BR112022019387A BR112022019387A2 BR 112022019387 A2 BR112022019387 A2 BR 112022019387A2 BR 112022019387 A BR112022019387 A BR 112022019387A BR 112022019387 A BR112022019387 A BR 112022019387A BR 112022019387 A2 BR112022019387 A2 BR 112022019387A2
Authority
BR
Brazil
Prior art keywords
aryl hydrocarbon
hydrocarbon receptor
ahr
receptor modulators
aminopyrimidine derivatives
Prior art date
Application number
BR112022019387A
Other languages
English (en)
Inventor
Park Jung-Sang
Cha Daewon
Lee Wonhyung
Sung Joo Min
Yoon Taeyoung
Doh Hyounmie
Jung Sung Hyun
Ryeong Lee Bo
Song Seunghyun
Kim Yoonjung
Hoon Choi Ji
Seok Jung Hyeon
Original Assignee
Dong A St Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong A St Co Ltd filed Critical Dong A St Co Ltd
Publication of BR112022019387A2 publication Critical patent/BR112022019387A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

DERIVADOS DE AMINOPIRIMIDINA E SEU USO COMO MODULADORES DE RECEPTORES DE ARIL HIDROCARBONETOS. A presente invenção se refere a novos compostos eficazes como moduladores do receptor de hidrocarboneto de arila (AhR), composição farmacêutica compreendendo os compostos para a modulação de AhR ou prevenção ou tratamento de uma doença, distúrbio ou condição associada à atividade de AhR, como ingrediente ativo, e assim, pode ser útil como um medicamento para a prevenção ou tratamento de uma doença, distúrbio ou condição associada à atividade de AhR, em particular, câncer, condição cancerosa, tumor, doença fibrótica, condição com respostas imunes desreguladas etc.
BR112022019387A 2020-03-27 2021-03-29 Derivados de aminopirimidina e seu uso como moduladores de receptores de aril hidrocarbonetos BR112022019387A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063000584P 2020-03-27 2020-03-27
PCT/KR2021/003883 WO2021194326A1 (en) 2020-03-27 2021-03-29 Aminopyrimidine derivatives and their use as aryl hydrocarbon receptor modulators

Publications (1)

Publication Number Publication Date
BR112022019387A2 true BR112022019387A2 (pt) 2022-11-16

Family

ID=77892076

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022019387A BR112022019387A2 (pt) 2020-03-27 2021-03-29 Derivados de aminopirimidina e seu uso como moduladores de receptores de aril hidrocarbonetos

Country Status (10)

Country Link
US (1) US20230150970A1 (pt)
EP (1) EP4126839A4 (pt)
JP (1) JP2023520988A (pt)
KR (1) KR20230005844A (pt)
CN (1) CN115397818A (pt)
AU (1) AU2021242143B2 (pt)
BR (1) BR112022019387A2 (pt)
CA (1) CA3176957A1 (pt)
MX (1) MX2022011826A (pt)
WO (1) WO2021194326A1 (pt)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3922735A1 (de) * 1989-07-11 1991-01-24 Hoechst Ag Aminopyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide
JP4105948B2 (ja) * 2000-09-15 2008-06-25 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用なピラゾール化合物
US7138404B2 (en) * 2001-05-23 2006-11-21 Hoffmann-La Roche Inc. 4-aminopyrimidine derivatives
EP1417180B1 (en) * 2001-07-13 2006-12-27 AstraZeneca UK Limited Preparation of aminopyrimidine compounds
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2010096619A1 (en) * 2009-02-23 2010-08-26 Wyeth Llc Process, purification and crystallization of 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
ES2365960B1 (es) * 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
KR101328978B1 (ko) * 2010-10-26 2013-11-13 삼성디스플레이 주식회사 유기 발광 소자
KR101556317B1 (ko) * 2013-10-29 2015-10-01 한국과학기술연구원 Ｒｏｓ 카이네이즈 저해활성을 갖는 2,4,6-삼치환된 피리미딘 화합물
EP3134388B1 (en) * 2014-04-22 2019-01-09 Universität Basel Novel manufacturing process for triazine, pyrimidine and pyridine derivatives
US11008280B2 (en) * 2016-04-26 2021-05-18 Duk San Neolux Co., Ltd. Compound for organic electric element, organic electric element using same, and electronic device comprising same organic electronic element
CN109863140B (zh) * 2016-05-25 2023-02-21 拜耳医药股份有限公司 3-氧代-2,6-二苯基-2,3-二氢哒嗪-4-甲酰胺
PT3570844T (pt) * 2017-01-20 2023-11-15 Arcus Biosciences Inc Azolopirimidina para o tratamento de doenças relacionadas com o cancro
JOP20190193A1 (ar) * 2017-02-09 2019-08-08 Bayer Pharma AG ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان
TWI778050B (zh) * 2017-04-21 2022-09-21 美商醫肯納腫瘤學公司 吲哚ahr抑制劑及其用途
CN110343095A (zh) * 2018-04-08 2019-10-18 中国科学院上海药物研究所 一类精氨酸甲基转移酶抑制剂及其药物组合物和用途

Also Published As

Publication number Publication date
EP4126839A1 (en) 2023-02-08
EP4126839A4 (en) 2024-04-17
CA3176957A1 (en) 2021-09-30
US20230150970A1 (en) 2023-05-18
WO2021194326A1 (en) 2021-09-30
MX2022011826A (es) 2022-10-18
KR20230005844A (ko) 2023-01-10
CN115397818A (zh) 2022-11-25
JP2023520988A (ja) 2023-05-23
AU2021242143B2 (en) 2024-07-18
AU2021242143A1 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
BR112022020965A2 (pt) Derivados de piridopirimidinona e seu uso como moduladores de receptores de hidrocarboneto arila
BR112022008858A2 (pt) Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
Niehr et al. Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations
Good et al. Intralesional agents in the management of cutaneous malignancy: a review
CL2019003589A1 (es) Derivado de n2,n4-difenilpirimidin-2,4-diamina, método para la preparación del mismo, y una composición farmacéutica que contiene el mismo como ingrediente activo para la prevención o tratamiento de cáncer.
BR112022012637A2 (pt) Composto de piridazinil-tiazolcarboxamida, composição farmacêutica e inibidor da dgk ¿ que compreendem o mesmo e uso do dito composto para tratar câncer relacionado à ativação das células imunes ou câncer tendo resistência à terapia com anticorpo anti-pd-1 / anticorpo anti-pd-l1
BR112022002237A2 (pt) Tratamento de distúrbios do sistema nervoso central
BR112021016296A2 (pt) Formulações tópicas de rapamicina e seu uso em tratamento de angiofibromas faciais e outros distúrbios de pele
BRPI0606707A2 (pt) uréias dissubstituìdas como inibidores de quinase
Greb et al. High-dose ustekinumab for the treatment of severe, recalcitrant pyoderma gangrenosum.
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
CL2023000881A1 (es) Compuestos y su uso en el tratamiento del cáncer
BR112021016833A2 (pt) Compostos com atividade indutora de ferroptose e métodos de seu uso
BR112022023983A2 (pt) Compostos terapêuticos
BR112022009805A2 (pt) Derivados de piridopirimidinona como antagonistas de ahr
BR112022000382A2 (pt) Administração de agonista de sting e inibidores de checkpoint
Jeong et al. The effect of rigorous study design in the research of autologous bone marrow-derived mononuclear cell transfer in patients with acute myocardial infarction
BR112021018591A2 (pt) Compostos e usos dos mesmos
BR112023016590A2 (pt) Inibidores de tyk2 e seus usos
BR112021026170A2 (pt) Composição farmacêutica para tratamento de tumor??
BR112013024909A2 (pt) composto, composição farmacêutica, método para o tratamento, prevenção ou melhoria de um ou mais sintomas de desordem, doença, ou condição mediada por pi3k, e método para modular a atividade enzimática de pi3k
Sollie et al. Autologous fat grafting seems to alleviate postherpetic neuralgia–a feasibility study investigating patient-reported levels of pain
Steffen et al. Botulinum toxin for salivary disorders in the treatment of head and neck cancer
BR112022019387A2 (pt) Derivados de aminopirimidina e seu uso como moduladores de receptores de aril hidrocarbonetos
Teng et al. Evaluating laser photobiomodulation for chemotherapy-induced peripheral neuropathy: a randomised phase II trial